🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity · Phase II

Metabolic & obesity programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
210

Quick answer

Metabolic & obesity Phase II programs: NovaPharmaNews indexes 210 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 3 of 5

  1. LGD-6972-5 mg

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  2. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  3. LX4211 Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  4. LX9211

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  5. Ladarixin, Placebo to match Ladarixin

    Dompe' Farmaceutici S.p.A.

    Recent onset Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  6. MB07803

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  7. MLN1202 Placebo

    Takeda

    Diabetic Nephropathy

    phase 2 small molecule terminated

    1 trial

  8. MSC

    Shandong University

    Type 2 Diabetes

    phase 2 mab active

    1 trial

  9. MSC and PRP

    Hospital Authority, Hong Kong

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  10. Matching Placebo

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  11. MenSCs transplantation

    The First People's Hospital of Lianyungang

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  12. Miricorilant

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials

  13. Miricorilant (Cohort A)

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  14. Motivational Interviewing

    Cardiff Oncology

    Diabetes Mellitus

    phase 2 other terminated

    1 trial

  15. NAT01, NAT03, Placebo film coated tablets, NAT02

    Dr. Falk Pharma GmbH

    Idiopathic or Diabetic Gastroparesis

    phase 2 small molecule active

    1 trial

  16. Naltrexone hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Obesity

    phase 2 small molecule active

    1 trial

  17. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial

  18. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  19. ORMD 0801

    ORAMED PHARMACEUTICALS INC.

    Brittle Type I Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  20. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  21. ORMD-0801 (Insulin) capsule 8 mg BD

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  22. ORMD-0801 Capsules

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 1

    phase 2 mab completed

    1 trial

  23. ORMD-0801 Dose # 1

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  24. ORMD-0801 QD

    ORAMED PHARMACEUTICALS INC.

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  25. ORMD-0801 Treatment A

    ORAMED PHARMACEUTICALS INC.

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  26. ORMD-0801 capsules- 2x8mg

    ORAMED PHARMACEUTICALS INC.

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  27. Olatorepatide

    Regeneron UK Limited

    Overweight or Obesity

    phase 2 small molecule active

    1 trial

  28. Omnitram Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  29. Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion

    Lacuna Pharma Pty Ltd

    Diabetic Retinopathy, Retinal Vein Occlusion

    phase 2 other active

    1 trial

  30. Oral Insulin

    ORAMED PHARMACEUTICALS INC.

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 mab completed

    1 trial

  31. Oshadi Icp

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus, Insulin-Dependent, 1

    phase 2 small molecule completed

    1 trial

  32. PEX168 or placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  33. PRAM9

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    1 trial

  34. PREGABALIN, VX-993 tablet, VX-993 Placebo, VX-993 tablet, PREGABALIN, Pregabalin placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Pain Associated With Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  35. Para-Tabs 500 mg tabletti, ODM-111 Placebo, ODM-111, ODM-111

    Orion Laboratories Pty.

    CHRONIC PAIN DUE TO DIABETIC PERIPHERAL NEUROPATHY

    phase 2 small molecule active

    1 trial

  36. Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  37. Pear

    NORTHWEST BIOTHERAPEUTICS INC

    Metabolic Syndrome

    phase 2 other completed

    1 trial

  38. Phosphate buffered saline for SC administration

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  39. Pioglitazone and azilsartan

    Takeda

    Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  40. Placebo

    IONIS PHARMACEUTICALS INC

    NAFLD

    phase 2 small molecule completed

    1 trial

  41. Placebo

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  42. Placebo (blinded)

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  43. Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Type 2 diabetes and painful diabetic peripheral neuropathy

    phase 2 small molecule active

    1 trial

  44. Placebo A, NNC0487-0111, NNC0487-0111, NNC0487-0111, Placebo C tablets, NNC0487-0111, METFORMIN , NNC0487-0111, NNC0487-0111, NNC0487-0111, DAPAGLIFLOZIN , NNC0487-0111

    NovoThirteen

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  45. Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  46. Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  47. Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  48. Placebo for AMG 133, AMG 133

    Amgen

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity Phase II programs exist?

210 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.